直接口服抗凝药与华法林对择期内镜后消化道出血及血栓栓塞事件的影响
这项回顾性队列研究纳入2013至2019年南加州大型医疗系统中接受门诊消化道内镜且术前服用DOAC或华法林的成人患者,比较术后30天内消化道出血和血栓栓塞风险。结果显示两组总体出血和血栓栓塞风险无显著差异,但亚组分析提示DOAC与EGD操作后出血风险升高相关。
要点
- DOAC与华法林组总体术后30天消化道出血和血栓栓塞风险无显著差异
- 亚组分析中DOAC与EGD操作后消化道出血风险升高相关
- 择期内镜术前抗凝管理需结合操作类型个体化评估
核心结论
- 术前使用DOAC与华法林的患者总体内镜后消化道出血和血栓栓塞风险无显著差异。
- 服用DOAC并接受EGD的患者可能存在更高的消化道出血风险。
研究设计与样本
- 共识别6765例次门诊内镜操作,其中DOAC组1587例次,华法林组5178例次。
- 采用多因素logistic回归分析比较内镜术后30天内出血和血栓风险,并校正协变量。
临床怎么用
- 择期内镜术前评估抗凝方案时,DOAC与华法林的总体出血和血栓风险相似。
- 对于服用DOAC并计划接受EGD的患者,应警惕术后消化道出血风险可能升高。
局限性
- 本研究为回顾性队列研究,可能存在未校正的混杂因素。
- 亚组分析结果需谨慎解读,可能受多重比较影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: An increasing number of patients are undergoing GI endoscopic procedures with active prescriptions for direct oral anticoagulants (DOACs). DOACs have been associated with a higher risk of GI bleeding (GIB) compared with warfarin. Our aims were to compare the risk of postendoscopic GIB and thromboembolic (TE) events among patients on DOACs versus warfarin. METHODS: We conducted a retrospective cohort study of patients aged 18 years or older in a large integrated health care system in Southern California, who had undergone an outpatient GI endoscopic procedure and were taking a DOAC or warfarin between January 1, 2013, and October 1, 2019. We compared bleeding and thrombosis risk in the 30 days after the endoscopic procedure between the warfarin and DOAC groups using multivariate logistic regression analysis adjusted for covariates. RESULTS: Between January 1, 2013, and October 1, 2019, we identified 6765 outpatient GI endoscopic procedures in which patients received preprocedure prescriptions for either a DOAC (1587) or warfarin (5178). Overall, there was no significant difference in postprocedure GIB (odds ratio [OR], 1.165; 95% confidence interval [CI], 0.88-1.55; P = .291) or TE (OR, 0.929; 95% CI, 0.64-1.35; P = .703) between the DOAC and warfarin groups). Subgroup analysis revealed a higher risk of GIB associated with DOAC specifically with EGD procedures (OR, 1.8; 95% CI, 1.15-2.83; P = .011). CONCLUSIONS: There was no significant difference in the overall postendoscopic risk of GIB and TE events among patients with preprocedure use of DOACs compared with patients on warfarin. There may be a higher risk of GIB in patients taking DOACs and undergoing EGD.
引用
- Tien A, Kwok K, Dong E, et al. Impact of direct-acting oral anticoagulants and warfarin on postendoscopic GI bleeding and thromboembolic events in patients undergoing elective endoscopy. Gastrointest Endosc. 2020. PMID: 32126220. doi:10.1016/j.gie.2020.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。